-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Haemonetics, Lowers Price Target to $80

Benzinga·02/06/2026 14:20:42
Listen to the news
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $90 to $80.